Compare · MASI vs TMDX
MASI vs TMDX
Side-by-side comparison of Masimo Corporation (MASI) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASI and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.31B, about 2.7x TMDX ($3.41B).
- Over the past year, MASI is up 11.0% and TMDX is up 6.0% - MASI leads by 5.0 points.
- TMDX has been more active in the news (6 items in the past 4 weeks vs 4 for MASI).
- MASI has more recent analyst coverage (24 ratings vs 17 for TMDX).
- Company
- Masimo Corporation
- TransMedics Group Inc.
- Price
- $178.43-0.02%
- $97.40-1.17%
- Market cap
- $9.31B
- $3.41B
- 1M return
- +0.34%
- -1.99%
- 1Y return
- +10.96%
- +5.95%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2019
- News (4w)
- 4
- 6
- Recent ratings
- 24
- 17
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest MASI
- Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
- SEC Form DEFA14A filed by Masimo Corporation
- Masimo Corporation filed SEC Form 8-K: Other Events
- Telix Strengthens Board with Additional Director Appointments
- SEC Form DEFM14A filed by Masimo Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation
- Masimo downgraded by Raymond James
- SEC Form PREM14A filed by Masimo Corporation
- CEO Szyman Catherine M. covered exercise/tax liability with 1,069 shares and converted options into 2,101 shares, increasing direct ownership by 16% to 7,605 units (SEC Form 4)
- EVP & Chief Financial Officer Young Micah W converted options into 873 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 2% to 25,656 units (SEC Form 4)
Latest TMDX
- TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
- TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
- TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
- SEC Form DEFA14A filed by TransMedics Group Inc.
- SEC Form DEF 14A filed by TransMedics Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.
- SEC Form 3 filed by new insider Forsyth Matthew S.
- Director Lovell Stephanie sold $178,497 worth of shares (1,193 units at $149.62), decreasing direct ownership by 29% to 2,866 units (SEC Form 4)
- Director Weill David exercised 3,571 shares at a strike of $14.20 and sold $524,294 worth of shares (3,571 units at $146.82) (SEC Form 4)